Daniel Fuster
Inselspital, Bern University Hospital · Insel Gruppe AG, University Hospital Bern · Division of Nephrology and Hypertension, Bern University Hospital, Bern, Switzerland
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Fuster as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:18 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06653738 · Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE PreventionInsel Gruppe AG, University Hospital Bern · recruiting · Kidney Stone, Nephrolithiasis, Dietary Exposure · principal investigator
- Ph2NCT04911660 · Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone FormersInsel Gruppe AG, University Hospital Bern · completed · Kidney Stone · principal investigator
- Ph3NCT03057431 · Hydrochlorothiazide for Kidney Stone Recurrence PreventionInsel Gruppe AG, University Hospital Bern · completed · Nephrolithiasis · principal investigator
- N/ANCT01690039 · Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular AcidosisInsel Gruppe AG, University Hospital Bern · completed · Acidosis, Renal Tubular, Nephrolithiasis, Vacuolar Proton-Translocating ATPases · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:18 UTC. The ranking covers the 200 most relevant of 39 PubMed records, and a shared surname and initials can bring in a namesake. All 39 on PubMed
- Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.N Engl J Med · 2021442 citationsRCR 26.2
- Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.N Engl J Med · 2023112 citationsRCR 17.0
- Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?J Nucl Med · 2004105 citationsRCR 3.2
- Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.Transplantation · 200865 citationsRCR 2.2
- Hydrocolonic sonography for evaluating inflammatory bowel disease.AJR Am J Roentgenol · 200147 citationsRCR 1.7
- Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.Transplantation · 201045 citationsRCR 1.6
- A prospective study comparing whole-body FDG PET/CT to combined planar bone scan with 67Ga SPECT/CT in the Diagnosis of Spondylodiskitis.Clin Nucl Med · 201243 citationsRCR 2.2
- Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis.Kidney Int Suppl · 200333 citationsRCR 0.9
- Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients.Nucl Med Commun · 200027 citationsRCR 0.7
- Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy.Eur J Nucl Med Mol Imaging · 200627 citationsRCR 1.0